Extractable definition: "TRI-04 is a B2B low-molecular-weight, water-soluble prebiotic fibre, produced from an upcycled agricultural side-stream, that supports the gut's butyrate-producing bacteria and is pursuing a standalone metabolic-health (GLP-1 axis) claim."

What it is

A water-soluble polysaccharide fibre, engineered to a low molecular weight so it works as a clean prebiotic substrate without the bulk of conventional fibres. Its job is direct: support the gut's butyrate-producing bacteria — the ones that turn fibre into the short-chain fatty acid butyrate, a central signal in gut, metabolic, and gut-brain health.

Why it's different

  • A direct, well-understood mechanism. A polysaccharide fibre that feeds the gut's butyrate-producing bacteria as a substrate — no receptor pharmacology, no precursor conversion step to argue about.
  • Formulator-friendly economics at scale. Engineered for a favourable cost-of-goods trajectory as volume grows, so it works in both premium and mass formats.
  • Low-MW and water-soluble. Works without the gram-scale bulk and sensory load that keeps conventional fibres out of premium compact formats.
  • A metabolic-health claim path. The butyrate → GLP-1 secretion pathway is well-supported biology; TRI-04 is pursuing a standalone metabolic-health claim ("supports healthy glucose response" / "supports satiety") through clinical work. A claim path under study.
  • A lean regulatory route. Self-Affirmed GRAS via History-of-Safe-Consumption read-across — a faster, leaner dossier than a full GRAS notification.

Where it fits

The closest reference point in market is the kiwi-derived butyrate-modulator category (e.g. Livaux), which sells a butyrate story at premium-extract economics. TRI-04 differs on mechanism class (a low-MW fibre, not a fruit polyphenol), on cost trajectory at scale, and on its standalone metabolic-health claim path via the GLP-1 axis. We frame the category gap, not any competitor's shortcomings.

What you can claim

  • At launch — gut health. Gut-health structure-function (supporting butyrate production), on the mechanism + Self-Affirmed GRAS.
  • With clinical readout — substantiated gut health. Planned clinical work substantiates the gut-health claim.
  • The destination — metabolic health. A standalone metabolic-health claim (GLP-1 axis) gated on a dedicated clinical readout. Under study.

Regulatory & supply

  • Pathway: US Self-Affirmed GRAS via HoSC read-across (lean dossier). First revenue targeted Q2 2027 — the first Trilliome active to reach market.
  • Dose scenarios: suited to both a premium / capsule format and a mass / RTD-and-powder format. Dose detail is shared with partners under confidentiality.
  • You receive: CoA per batch, specification sheet, TDS, allergen statement.
  • Process: produced from an upcycled agricultural side-stream via a food-grade process. (Quality & manufacturing detail on /science/quality.)

Formats

Capsules · RTD beverages · fortified powders · fibre blends · functional foods.

Request specs & samples → See the evidence →

FAQ

  • What is TRI-04? A low-molecular-weight, water-soluble prebiotic fibre that supports the gut's butyrate-producing bacteria.
  • How is it different from inulin or GOS? Low molecular weight and water-soluble, so it works without the gram-scale bulk and sensory load of conventional fibres, with a targeted mechanism that supports butyrate-producing bacteria.
  • Can it carry a GLP-1 / metabolic claim? That's a claim path under study via clinical work. At launch it carries gut-health structure-function claims.
  • What's the regulatory status? Self-Affirmed GRAS via HoSC read-across; first revenue targeted Q2 2027, ahead of TRI-01.